Flamingo-01 Phase III GP2 Product Press Releases Email Alerts
Greenwich LifeSciences
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED CLINICAL TRIALS
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GLSI-100 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED CLINICAL TRIALS
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT

Press Releases

Nasdaq: GLSI

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Presentations
    • FAQ
  • Stock Info
  • SEC Filings
  • Governance
  • News & Events

  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 24, 2022 6:00am EST

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Dec 15, 2021 6:00am EST

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Dec 09, 2021 6:29am EST

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Dec 08, 2021 7:00am EST

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Dec 07, 2021 6:34am EST

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Dec 06, 2021 7:15am EST

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Nov 18, 2021 6:00am EST

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Nov 17, 2021 6:00am EST

Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference

Nov 11, 2021 6:00am EST

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

Nov 10, 2021 7:00am EST

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
RSS

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

Sign me up for:

  • Tear Sheet
  • RSS Feed
Logo of Greenwich LifeSciences.

Copyright © 2025

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
X logo
Privacy Policy
Disclaimer
Sitemap
Logo of Greenwich LifeSciences.

Copyright © 2025

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Disclaimer
Privacy Policy
Sitemap
X logo